Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial

173Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

A number of uncontrolled studies have indicated that oral administration of amrinone, a phosphodiesterase inhibitor with potent positive inotropic effects in experimental preparations, may be beneficial in patients with chronic congestive heart failure. The present multicenter trial was designed to prospectively evaluate clinical response and change in exercise tolerance during 12 weeks of amrinone therapy in a double-blind, placebo-controlled protocol. Ninety-nine patients with NYHA functional class 3 or 4 congestive heart failure on digitalis and diuretics, of whom 31 were also receiving captopril, were enrolled. After baseline clinical assessment and determination of exercise tolerance, radionuclide left ventricular ejection fraction, and roentgenographic cardiothoracic ratio, patients were randomly assigned to receive amrinone or placebo, beginning at 1.5 mg/kg tid and increasing to a maximum dosage of 200 mg tid. After 12 weeks of therapy or at the last blinded evaluation in patients who did not complete this protocol, there were no significant differences from baseline values between treatment with amrinone or placebo with regard to symptoms, NYHA functional class, left ventricular ejection fraction, cardiothoracic ratio, frequency and severity of ventricular ectopy, or mortality. Exercise tolerance improved significantly from baseline by 37 ± 10% (mean 163 sec) in patients on amrinone and 35 ± 11% (mean 149 sec) in patients on placebo, but there was no significant difference between treatments. Adverse reactions were significantly more frequent and more severe on amrinone, occurring in 83% of patients and necessitating withdrawal in 34%. Downward adjustment of amrinone dosage because of side effects was responsible for a significantly lower mean total daily dose of 355 vs 505 mg for placebo (P < .001). These findings indicate that oral administration of amrinone is not clinically effective in patients with chronic congestive heart failure, in part because of frequent adverse effects.

Cited by Powered by Scopus

Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure

2066Citations
N/AReaders
Get full text

2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the Aamerican College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation

1481Citations
N/AReaders
Get full text

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation

1415Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Massie, B., Bourassa, M., DiBianco, R., Hess, M., Konstam, M., Likoff, M., & Packer, M. (1985). Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial. Circulation, 71(5), 963–971. https://doi.org/10.1161/01.CIR.71.5.963

Readers over time

‘11‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

55%

Professor / Associate Prof. 5

25%

Researcher 4

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 17

68%

Nursing and Health Professions 4

16%

Pharmacology, Toxicology and Pharmaceut... 2

8%

Veterinary Science and Veterinary Medic... 2

8%

Save time finding and organizing research with Mendeley

Sign up for free
0